Welcome to our dedicated page for Adaptive Biotechnologies SEC filings (Ticker: ADPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Adaptive Biotechnologies Corporation (ADPT) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed, commercial-stage biotechnology company, Adaptive Biotechnologies uses these filings to report financial results, material agreements, and other significant corporate events related to its Minimal Residual Disease (MRD) and Immune Medicine businesses.
Among the key documents are current reports on Form 8-K, which the company files to furnish earnings press releases and to describe material events. For example, Adaptive Biotechnologies has filed Form 8-K reports to present quarterly financial results, including segment revenue for its MRD and Immune Medicine businesses, and to disclose the termination of a Strategic Collaboration and License Agreement with Genentech, Inc. related to cancer cell therapy research and development. These filings may also outline expected accounting impacts, such as recognition of remaining non-cash revenue from prior collaboration payments.
In addition to 8-Ks, investors typically look to annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) for more detailed information on revenue composition, operating expenses, segment performance, risk factors, and management’s discussion and analysis. For a company like Adaptive Biotechnologies, these periodic reports help explain how its clonoSEQ MRD business and Immune Medicine programs contribute to overall results, as well as how it manages cash burn targets and investment in research and development.
On this page, Stock Titan pairs real-time updates from the SEC’s EDGAR system with AI-powered summaries that highlight the main points of each filing. Users can quickly see which filings relate to earnings announcements, collaboration changes, or other material events, and can use the underlying documents to analyze ADPT’s financial condition, strategic focus, and progress in MRD and immune medicine initiatives.
Adaptive Biotechnologies Corp CEO and Chairman Chad M. Robins reported open-market sales of company common stock executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 11, 2025.
He sold 83,332 shares on April 6, 2026 at a weighted average price of $14.41 per share in multiple trades between $14.19 and $14.84. He then sold 37,263 shares on April 8, 2026 at a weighted average price of $15.19 per share, with individual trades between $15.00 and $15.53.
Across both transactions, Robins sold 120,595 shares and directly held 2,180,518 shares of Adaptive Biotechnologies common stock following the most recent sale.
Adaptive Biotechnologies Corp President and COO Julie Rubinstein reported option exercises and share sales in a planned series of trades. She exercised stock options for 56,047 shares of common stock at exercise prices of $7.27 and $12.14 per share and sold 69,061 shares in open‑market transactions at weighted average prices ranging from about $13.39 to $15.48 between April 6 and April 8, 2026. After these transactions, she directly held 434,188 shares of common stock and retained vested stock options representing 37,553 shares. The filing notes that all transactions were carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 18, 2025.
ADPT affiliate reported proposed resale of Common Stock under Form 144. The cover lists 10,000 shares associated with a broker, an aggregate figure of $148,400, and 153,981,561 shares outstanding as of 04/08/2026. The filing also lists multiple recent dispositions by Harlan Robins, including sales on 02/02/2026, 02/03/2026, 03/02/2026, and 03/03/2026 totaling several reported share amounts and proceeds.
Chad M. Robins reported proposed and recent transactions in Common Stock under a Form 144. The filing lists multiple individual sales and proposed sales of common stock, including transactions in February–April 2026. Examples in the filing include a sale of 99,225 shares for $1,589,941.71 on 02/27/2026 and a sale of 96,323 shares for $1,546,542.82 on 03/02/2026. The document is a notice of proposed sale by an affiliate and lists several executed dispositions in the prior three months.
ADPT affiliate files Form 144 to sell shares. The filing lists 2,344 shares to be sold upon exercise of stock options dated 04/08/2026 and 20,220 shares issuable under Restricted Stock Units dated 03/04/2025. The filing also reports recent 10b5-1 sales: 30,593 shares on 03/11/2026 for $430,622.58, 38,074 shares on 03/05/2026 for $574,536.66, and 79,590 shares on 01/12/2026 for $1,411,393.35.
Adaptive Biotechnologies (ADPT) notice of proposed sales of Common Stock by an affiliate under Form 144. The excerpt lists multiple proposed sale transactions by Chad M. Robins with individual trades ranging from 4,452 to 99,225 shares and corresponding gross proceeds shown per trade.
Adaptive Biotechnologies President and COO Julie Rubinstein exercised stock options and sold shares in pre-planned transactions. She exercised options to acquire 29,444 shares of common stock at $7.27 per share, then sold 38,120 shares of common stock in open-market trades at weighted average prices of $14.45 and $14.60 per share.
All transactions were effected under a Rule 10b5-1 trading plan adopted on November 18, 2025, indicating they were pre-scheduled. Following these trades, Rubinstein directly holds 447,202 shares of Adaptive Biotechnologies common stock.
Adaptive Biotechnologies President and COO Julie Rubinstein reported a series of option exercises and related share sales in late March. She exercised stock options for 44,166 shares of common stock at an exercise price of $7.27 per share, then sold 57,180 shares of common stock in open-market transactions at prices in the $12–$13 range. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025. Following the trades, she directly holds 455,878 shares of Adaptive Biotechnologies common stock.
Adaptive Biotechnologies President and COO Julie Rubinstein reported a series of option exercises and related stock sales in common stock. Over March 24–26, she exercised stock options to acquire a total of 44,166 shares of common stock at an exercise price of $7.27 per share. She then sold 57,180 shares in open-market transactions at weighted average prices ranging from $13.45 to $14.49 per share. Following these transactions, she directly holds 468,892 shares of Adaptive Biotechnologies common stock. The filing notes that all transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025.
The Vanguard Group filed Amendment No. 6 to a Schedule 13G/A reporting 0 shares (0%) of Adaptive Biotechnologies Corp common stock. The filing explains an internal realignment that disaggregated certain Vanguard subsidiaries' holdings in reliance on SEC Release No. 34-39538, so Vanguard reports no beneficial ownership here. The form is signed by Ashley Grim, Head of Global Fund Administration on 03/26/2026.